Share Twitter LinkedIn Facebook Email Chadi Nabhan MD, MBA, FACP @chadinabhan of Caris Life Sciences @carisls discusses the characterizations of KRAS mutations in non-small cell lung cancer. Read here: https://meetinglibrary.asco.org/record/184890/abstract Advertisement
Targeting SCD1 in KRAS Mutant Non-Small Cell Lung Cancer: A Novel Therapeutic Strategy Non-Small Cell Lung Cancer 3 Mins Read
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read